Table 2.

Summary of studies on COVID-19 vaccines included in the systematic review.

Authors, Year [Ref]	Vaccine	Country/ Region	Platform	Population	Study Design	Period	Sample Size	Number of Doses	Route of Administration
L.R. Baden et al., 2021 [19]	mRNA-1273	US	mRNA	≥18 years old	Single-blind, randomized, controlled trial	27 July–23 October 2020	30,420	2	Intramuscular
Merryn Voysey et al., 2020 [20]	AZD1222	UK, Brazil, South Africa	Non-Replicating Viral Vector	≥18 years old	Single-blind, randomized, controlled trial	24 April–4 November 2020	23,848	2	Intramuscular
Denis Y Logunov et al., 2021 [21]	Gam-COVID-Vac	Russia	Non-Replicating Viral Vector	≥18 years old	Double-blind, randomized, controlled trial	7 September–24 November 2020	21,977	2	Intramuscular
Fernando P. Polack et al., 2020 [22]	BNT162b2	US, Argentina, Brazil, South Africa	mRNA	≥16 years old	Single-blind, randomized, controlled trial	27 July–14 November 2020	44,820	2	Intramuscular
Katherine R W Emary et al., 2021 [23]	AZD1222	UK	Non-Replicating Viral Vector	≥18 years old	Single-blind, randomized, controlled trial	31 May–13 November 2020	8534	2	Intramuscular
J. Sadoff et al., 2021 [24]	Ad26.COV2.S	Argentina, Brazil, Chile, Colombia, Mexico, Peru South Africa, US	Non-Replicating Viral Vector	≥18 years old	Double-blind, randomized, controlled trial	21 September 2020–22 January 2021	44,325	1	Intramuscular
Eric J Haas et al., 2021 [25]	BNT162b2	Israel	mRNA	≥16 years old	Observational study	24 January–3 April, 2021	6,538,911	2	Intramuscular
Noa Dagan et al., 2021 [26]	BNT162b2	Israel	mRNA	≥16 years old healthcare workers	Observational study	20 December 2020–1 February 2021	769,958	2	Intramuscular
Nick K Jones et al., 2021 [27]	BNT162b2	UK	mRNA	Healthcare workers	Observational study	18 January–31 January 2021	8819	1	Intramuscular
Melanie D. Swift et al., 2021 [28]	BNT162b2	US	mRNA	Healthcare workers	Observational study	1 January–31 March 2021	76,000	2	Intramuscular
Merryn Voysey et al., 2021 [29]	AZD1222	UK, Brazil, South Africa	Non-Replicating Viral Vector	≥18 years old	Randomized, controlled trial	23 April–6 December 2020	24,422	2	Intramuscular
Nawal Al Kaabi Et al., 2021 [30]	BBIBP-CorV	UAE, Bahrain	Inactivated	≥18 years old	Double-blind, randomized, controlled trial	16 July–31 December 2020	40,382	2	Intramuscular